Cargando…

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER

BACKGROUND: Clinical trials traditionally use time‐to‐first‐event analysis embedded within the composite endpoint of cardiovascular death (CVD), myocardial infarction (MI), or stroke. However, many patients have >1 event, and this approach may not reflect overall experience. We addressed this by...

Descripción completa

Detalles Bibliográficos
Autores principales:	White, Harvey D., Huang, Zhen, Tricoci, Pierluigi, Van de Werf, Frans, Wallentin, Lars, Lokhnygina, Yuliya, Moliterno, David J., Aylward, Philip E., Mahaffey, Kenneth W., Armstrong, Paul W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310394/ https://www.ncbi.nlm.nih.gov/pubmed/25012288 http://dx.doi.org/10.1161/JAHA.114.001032

Ejemplares similares

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
por: van Diepen, Sean, et al.
Publicado: (2015)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes
por: Mahaffey, Kenneth W, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
por: Cheng, Judy WM
Publicado: (2016)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
por: Farag, Mohamed, et al.
Publicado: (2015)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
por: Lopes, Renato D, et al.
Publicado: (2013)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

2159. Methodological Threats to the Standardized Infection and Standardized Antimicrobial Administration Ratios
por: Lofgren, Eric, et al.
Publicado: (2018)

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
por: Vergara-Jimenez, Jennifer, et al.
Publicado: (2010)

Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF-κB signaling pathways
por: Pang, Jianliang, et al.
Publicado: (2019)

Comparison of regression imputation methods of baseline covariates that predict survival outcomes
por: Solomon, Nicole, et al.
Publicado: (2020)

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid‐Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P‐TIMI 50 Trial
por: Gilchrist, Ian C., et al.
Publicado: (2021)

STUDIES OF THE TRIAD : II. Penetration of Tracers into the Junctional Gap
por: Franzini-Armstrong, Clara
Publicado: (1971)

Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy
por: Held, Claes, et al.
Publicado: (2022)

1823. Signal or Noise? A Comparison of Methods to Identify Outliers in Antimicrobial Use (AU)
por: Moehring, Rebekah W, et al.
Publicado: (2018)

Isotopic Tracers
Publicado: (1955)

Application of Isotope Tracer in Cross-Well Nanometre Tracer Testing
por: Pang, Yang, et al.
Publicado: (2022)

New protein deposition tracers in the pipeline
por: Jovalekic, Aleksandar, et al.
Publicado: (2016)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

Retracted: Application of Isotope Tracer in Cross-Well Nanometre Tracer Testing
por: Chemistry, International Journal of Analytical
Publicado: (2023)

Radioactive Tracers in Biology
por: Salter, William T.
Publicado: (1951)

Radioactive tracer techniques
por: Schweitzer, Georg K, et al.
Publicado: (1949)

Early recognition and response to increases in surgical site infections using optimized statistical process control charts—the Early 2RIS Trial: a multicenter cluster randomized controlled trial with stepped wedge design
por: Anderson, Deverick J., et al.
Publicado: (2020)

Click Chemistry in the Design and Production of Hybrid Tracers
por: Hensbergen, Albertus W., et al.
Publicado: (2019)

Occurrence of D-amino acids in natural products
por: Armstrong, Daniel W., et al.
Publicado: (2023)

PET Tracers for Imaging Cardiac Function in Cardio-oncology
por: Kelly, James M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mrevv3frh37m2lrre9vcau8efh